NCT05090566: Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM
Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy NCT05090566: Phase 2: MagnetisMM-4: Umbrella Study of...
Dec 1, 2021
243
NCT04827563: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
NCT04827563: Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib Observational Dyspnea and Cardiotoxicity in...
Jun 3, 2021
72
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
Talquetamab Phase 2 A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma A Study of Talquetamab in...
Dec 29, 2020
857
NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma
NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma This is a...
Dec 11, 2020
176
NCT04394650: Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
CC-98633 CART NCT04394650: Phase 1 - A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With...
Dec 1, 2020
207
NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With RRMM
NCT04318327: Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma This is a...
Dec 1, 2020
206
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
CARTITUDE-2 Ciltacabtagene Autoleuce A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell...
Dec 19, 2019
779
NCT04108624: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients Study to Assess for Measurable Residual Disease (MRD)...
Dec 13, 2019
318
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
CELMoD MM-002 CC-92480-MM-002 (NCT03989414) NCT03989414: A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety...
Dec 11, 2019
757
NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM
NCT04184050: Phase 1/2: Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217...
Dec 7, 2019
216
NCT04155749: Phase 1 : CART-ddBCMA - Master Protocol for Cell Therapies in Multiple Myeloma
NCT04155749: Phase 1: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma Master Protocol for the Phase 1 Study...
Dec 5, 2019
389
NCT03548207: Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in relapsed MM (CARTITUDE-1)
CARTITUDE-1 Ciltacabtagene Autoleucel autologous bi-epitope BCMA-targeted CAR T cells JNJ-68284528 LCAR-B38M cilta-cel The purpose of the...
Dec 26, 2018
690
NCT03430011: Phase 1/2 - Autologous BCMA-specific CAR-T cells JCARH125 in RRMM (EVOLVE)
EVOLVE Autologous BCMA-specific CAR-T cells JCARH125 NCT03430011: Phase 1/2 - Study Evaluating the Safety and Efficacy of JCARH125 in...
Dec 20, 2018
142
NCT03729804: Phase 3: KRd Versus VRd in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
NCT03729804: Phase 3: Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in...
Dec 13, 2018
137
NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
NCT03741127: Phase 1: Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 Recruitment Status: Enrolling by invitation...
Dec 8, 2018
129
NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM
Multiple Myeloma Research Consortium phase 2 study Dara-KRd NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose...
Dec 5, 2018
211
NCT03525678: Phase 2 - Two Doses of GSK2857916 in Myeloma who have failed Anti-CD38 Ab. DREAMM 2
DREAMM 2 Relapsed & Refractory Multiple Myeloma A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants...
Dec 4, 2018
374
NCT03274219 : Phase 1 - bb21217 an Anti-BCMA CAR T Cell Drug Product, in RRMM - CRB-402
CRB-402 Study of bb21217 in Multiple Myeloma Relapsed Refractory Multiple Myeloma RRMM Study CRB-402 is a 2-part, non-randomized, open...
Dec 29, 2017
423
NCT03158688: Phase 3 - Carfilzomib, Daratumumab and Dexa for relapsed Multiple Myeloma. (CANDOR)
Phase 3 CANDOR study Dara-Kd Kd Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple...
Dec 28, 2017
341